^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TBL1 inhibitor

    Related drugs:
    1m
    Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Emory University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • tegavivint (BC2059)
    4ms
    Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Emory University | Initiation date: Oct 2025 --> Jan 2026
    Trial initiation date
    |
    gemcitabine • tegavivint (BC2059)
    8ms
    Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Emory University
    New P1 trial
    |
    gemcitabine • tegavivint (BC2059)
    11ms
    A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=178, Recruiting, Iterion Therapeutics | N=108 --> 178
    Enrollment change
    |
    AXIN1 (Axin 1)
    |
    Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet) • tegavivint (BC2059)